MOTS-c: Mitochondrial Peptide Research in Metabolism and Longevity

Most peptides are encoded in your nuclear DNA, the genome people mean when they say your genome. MOTS-c isn’t. It’s written into the small, separate genome inside your mitochondria, the parts of the cell that make energy. That was the surprise when it was identified in 2015: the mitochondrial genome, long thought to code for almost nothing beyond the energy machinery, was producing a peptide that travels through the body and tweaks metabolism. Genuinely novel. Also genuinely untested in humans as a treatment. Both halves of that matter. So let’s start there.

What MOTS-c is

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c. It’s a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. The 2015 Cell Metabolism paper that reported it mattered for a specific reason: the mitochondrial genome was thought to encode only a handful of proteins for the electron transport chain, the cell’s energy-production line. MOTS-c showed it could also produce a bioactive peptide with systemic, hormone-like functions.

That mitochondrial origin is the part to keep straight. Mitochondria are the cell’s main energy producers. A peptide written into mitochondrial DNA, able to circulate and influence metabolism, is a genuinely new kind of signalling molecule. That’s the legitimate novelty claim. It is not the same as a treatment claim.

Humans do carry circulating MOTS-c. Observational studies find plasma levels drop with age and run lower in people with obesity and metabolic syndrome. That’s consistent with a role in metabolic regulation. It doesn’t establish cause, and a correlation in a blood draw is not a treatment effect.

What the mouse data shows — and the human data doesn’t

The interventional work is in mice. Worth saying first, because the exercise in a vial framing online won’t.

The 2015 Cell Metabolism paper by Lee and colleagues laid down the basic biology. MOTS-c promoted glucose uptake in muscle through an AMPK-dependent mechanism, cut fat accumulation in diet-induced obesity models, and partially corrected insulin resistance. In mice, dosing improved glucose tolerance and reduced body weight on high-fat diets.

A 2021 Nature Communications paper carried this into aging. In aged mice, MOTS-c restored physical performance, grip strength and treadmill tests, and the peptide moved into the nucleus under metabolic stress to regulate adaptive gene-expression programmes for metabolism and stress response. The authors called it an exercise-induced mitochondrial-encoded regulator. That phrasing is where the popular exercise mimetic label comes from. The label is doing more work in the headlines than the data does.

On the human side it’s observational. A 2022 review in the International Journal of Molecular Sciences gathers the human evidence: circulating MOTS-c declines with age and runs lower in people with metabolic dysfunction. That’s a pattern across observational studies, not a treatment effect.

Here’s the part that matters. Every interventional result, every effect from giving an animal MOTS-c, is in mice. The human data is association only: low MOTS-c tracks with worse metabolic health. That is not the same as showing that injecting MOTS-c makes a person healthier. Nobody has shown that.

Where MOTS-c sits on the docket

MOTS-c is on the PCAC July 23, 2026 docket — Day 1 of the two-day meeting, alongside BPC-157, KPV, and TB-500. Per Federal Register notice 2026-07361, the FDA-reviewed indications are obesity and osteoporosis — two conditions with real unmet need and a metabolic rationale that fits the preclinical work. A 503A listing is the route a compounding pharmacy uses to legally prepare something with no standalone drug approval, for a specific patient with a prescription.

It’s not on the FDA’s 503A or 503B approved bulk substances lists. Inclusion on the July docket is an early signal of regulatory interest, nothing more. The July review decides whether the FDA finds the evidence base adequate for a compounding pathway. Given MOTS-c was only characterised in 2015, this is early-stage compared with compounds studied for decades.

MOTS-c doesn’t appear on the WADA 2026 Prohibited List by name. If you compete, verify with your governing body anyway: the S2 category’s similar-effect language could be applied depending on how it’s classified.

What hasn’t been measured

This is the honest part, so read it twice.

The human interventional gap is the headline limitation. Low MOTS-c correlating with poor metabolic outcomes does not establish that giving someone MOTS-c improves those outcomes. The mouse effects need replication in human trials before they mean anything clinically.

Pharmacokinetics after subcutaneous injection in humans, absorption, distribution, half-life, clearance, haven’t been characterised in published studies.

Safety in humans isn’t established either. How exogenous MOTS-c interacts with your own mitochondrial signalling is not well understood, and what happens when you push circulating levels above the natural range is unknown.

The osteoporosis indication on the PCAC docket has even less preclinical support than the metabolic one, and the mechanistic case for it is thinner.

Where MOTS-c lands

MOTS-c is the real novelty in this space: mitochondrially encoded, recently discovered, mechanistically tied to cellular energy in a way that puts it in its own category. The preclinical metabolic data is interesting and plausible. The human evidence gap isn’t thin. It’s complete: no interventional human trials have been published.

The honest framing: the biology is genuinely new, the human column is empty, and July 23, 2026 is the first serious US regulatory engagement with the compound. Keep the novel-mechanism claim and the proven-in-people claim firmly apart. Watch what PCAC does.